Last reviewed · How we verify
Cardiac Decompensation — Treatment Landscape & Competitive Intelligence
2 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Dobutamine Hydrochloride In Dextrose 5% In Plastic Container | Dobutamine Hydrochloride | Pfizer Inc. | Inotropic agent | Beta-receptors of the heart | 1978-01-01 | |
| Dobutamin | Dobutamin | Competence Network for Congenital Heart Defects | Solute carrier family 22 member 1, Alpha-1D adrenergic receptor, Alpha-2B adrenergic receptor |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- · 1 drug in Cardiac Decompensation
- Competence Network for Congenital Heart Defects · 1 drug in Cardiac Decompensation
- Pfizer Inc. · 1 drug in Cardiac Decompensation
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Cardiac Decompensation:
- Cardiac Decompensation treatment updates — RSS
- Cardiac Decompensation treatment updates — Atom
- Cardiac Decompensation treatment updates — JSON
Cite this brief
Drug Landscape (2026). Cardiac Decompensation — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/cardiac-decompensation. Accessed 2026-06-10.
Related
- Cardiac Decompensation full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing